[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620514":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":27,"locations":35,"responsibleParty":54,"collaborators":19,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":58,"sex":64,"minAge":65,"maxAge":19,"enrollmentInfo":66,"targetDuration":19,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":38,"whyStopped":19,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Hospital Clinic of Barcelona","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Non-invasive mapping-guided ablation","EXPERIMENTAL","In this arm patients undergo a personalized ablation approach: In addition to conventional pulmonary vein isolation, additional target regions will be ablated based on non-invasive global mapping.",[13],"Procedure: Non-invasive mapping-guided ablation",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"PROCEDURE","The study intervention consists of\n\n1. Empirical pulmonary vein isolation (current standard of care) plus\n2. A personalized ablation approach targeting up to three additional atrial regions which harbour critical AF-perpetuating sources:\n\n   * Target regions are selected based on the spatiotemporal Stability of Atrial High-Rate Activity (SAHRA) using a non-invasive global mapping system (Acorys, Corify Care).\n   * Selected target regions displaying stable high-rate activity are isolated or homogenized according to predefined regional borders based on the 15-segment bi-atrial model of the EHRA and EACVI Clinical Consensus on Standardized Atrial Regionalization (Althoff et al. 2025).",[9],null,[21,25],{"name":22,"affiliation":23,"role":24},"Till F Althoff, M.D.","German Heart Center of the Charite, Berlin","PRINCIPAL_INVESTIGATOR",{"name":26,"affiliation":5,"role":24},"Ivo Roca-Luque, M.D., Ph.D.",[28,32],{"name":22,"role":29,"phone":30,"phoneExt":19,"email":31},"CONTACT","+49 30 450513143","till.althoff@dhzc-charite.de",{"name":26,"role":29,"phone":33,"phoneExt":19,"email":34},"+34 93 2271778","iroca@clinic.cat",[36],{"facility":37,"status":38,"city":39,"state":19,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Hospital Clinic, University of Barcelona","RECRUITING","Barcelona","08036","Spain","ES",{"type":44,"coordinates":45},"Point",[46,47],2.15899,41.38879,{"lat":47,"lon":46},[50,51],{"name":26,"role":29,"phone":19,"phoneExt":19,"email":34},{"name":52,"role":29,"phone":19,"phoneExt":19,"email":53},"Lluis Mont, M.D., Ph.D.","lmont@clinic.cat",{"type":55,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100620514","non-invasive-mapping-guided-atrial-fibrillation-ablation-100620514",false,"NCT07358611","Non-invasive Mapping-Guided Atrial Fibrillation Ablation","ELectrocardiographic Imaging-guided Substrate Ablation in Patients With Atrial Fibrillation - a PILOT Study of a Personalized Therapy","ELISA-AF","Inclusion Criteria:\n\nAblation-naïve patients with:\n\n1. Persistent AF planned for catheter ablation plus\n2. Left atrial enlargement (LA diameter ≥45 mm or LA volume index ≥35ml\u002Fm2 or LA area ≥20 cm2)\n\nExclusion Criteria:\n\n* Previous cardiac ablation\n* Age \\\u003C18 years\n* Pregnancy or lactation\n* Previous stroke\u002FTIA\n* Severe left ventricular dysfunction (LVEF \\\u003C35%)\n* Renal failure (GFR \\\u003C30 ml\u002Fmin)\n* Dermal disease or hypersensitivity predisposing for skin irritation or exanthema","ALL","18 Years",{"count":67,"type":68},30,"ESTIMATED","INTERVENTIONAL",[71],"NA","The goal of this pilot study is to test if noninvasive global mapping can guide catheter ablation defining personalized targets and improve the therapy of atrial fibrillation. It will also test the safety of such an approach. The main questions it aims to answer are:\n\n* Does ablation of targets defined by noninvasive global mapping improve rates of acute atrial fibrillation termination?\n* Does such a personalized ablation approach reduce arrhythmia recurrence rates? Researchers will compare the results of the personalized ablation approach with comparable patients that had undergone a conventional \"empirical\" ablation approach (pulmonary vein isolation).\n\nParticipants will:\n\n* Undergo a personalized catheter ablation approach employing both a noninvasive global mapping system and a conventional intracardiac mapping system\n* Visit the clinic 3, 6 and 12 months after ablation for clinical follow-up\n* Schedule a telephone visit 9 and 24 months after ablation for clinical follow-up",[74],"Atrial Fibrillation (AF)",[76,77,78,79,80,81,82],"Atrial fibrillation","Catheter ablation","Atrial fibrillation drivers","Personalized atrial fibrillation therapy","Electroanatomical mapping","Electrocardiographic imaging","Body surface mapping","2026-01-14",{"date":85,"type":86},"2026-01-22","ACTUAL",{"date":88,"type":68},"2026-01-31",{"date":90,"type":68},"2027-12-31",{"name":5,"class":6},1]